Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / GNTA - Genenta Welcomes New Directors John L. Cantello Lauren H. Chung Armon R. Sharei and Todd Wider | Benzinga


GNTA - Genenta Welcomes New Directors John L. Cantello Lauren H. Chung Armon R. Sharei and Todd Wider | Benzinga

  • MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman.

    "When Luigi Naldini, Ph.D., M.D., and I co-founded Genenta, we always aspired to involve leading figures in the biotech sector. This Board is fantastic. Our new directors will support Genenta as we aim to consolidate the important results we have achieved so far and to expand the potential impact of our cell therapy for treating tumors," said Pierluigi Paracchi.

    The Company extends its thanks to the former members of its Board for their significant contributions throughout their service.

    John L. Cantello, Ph.D.
    John is an independent advisor to the biopharma industry with over 20 years of experience. John served as the Former VP and Head of Business Development, Oncology Therapy Area at GlaxoSmithKline and VP and Head of BD, Respiratory & Immune Diseases at AstraZeneca. John has led teams accountable for assessing, valuing, and transacting M&A, pipeline & commercial asset deals covering oncology, respiratory, inflammation, metabolic, and rare diseases. He has a track record of closing deals (transacting >$30B in deal value) representing primary care, specialty care, and rare diseases.

    Lauren H. Chung, Ph.D.
    Lauren has over 20 years of ...

    Full story available on Benzinga.com

  • Stock Information

    Company Name: Genenta Science S.p.A.
    Stock Symbol: GNTA
    Market: NASDAQ
    Website: genenta.com

    Menu

    GNTA GNTA Quote GNTA Short GNTA News GNTA Articles GNTA Message Board
    Get GNTA Alerts

    News, Short Squeeze, Breakout and More Instantly...